Is Natco's Albupax Equivalent To Abraxis' Cancer Drug Abraxane? India's Drug Controller Probes
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Drug Controller General of India has launched an investigation to determine if Natco Pharma's generic breast cancer drug Albupax is therapeutically equivalent to Abraxis BioScience's original brand Abraxane. Natco's generic drug was given marketing approval last year September while Indian biotechnology company Biocon is marketing Abraxane in India following an agreement announced in July of last year